• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    I

    International Hereditary Cancer Center

    EST. 1992
    33论文总数
    2,859引用总数

    论文量&引用量时间轴

    机构学者

    论文(33)

    年份
    起
    –
    止
    排序
    1Pan-cancer Analysis of Non-Oncogene Addiction to DNA Repair
    Luis Bermúdez-Guzmán

    Cancer cells usually depend on the aberrant function of one or few driver genes to initiate and promote their malignancy, an attribute known as oncogene addiction. However, cancer cells might become dependent on the normal cellular functions of certain genes that are not oncogenes but ensure cell survival (non-oncogene addiction). The downregulation or silencing of DNA repair genes and the consequent genetic and epigenetic instability is key to promote malignancy, but the activation of the DNA-damage response (DDR) has been shown to become a type of non-oncogene addiction that critically supports tumour survival. In the present study, a systematic evaluation of DNA repair addiction at the pan-cancer level was performed using data derived from The Cancer Dependency Map and The Cancer Genome Atlas (TCGA). From 241 DDR genes, 59 were identified as commonly essential in cancer cell lines. However, large differences were observed in terms of dependency scores in 423 cell lines and transcriptomic alterations across 18 cancer types. Among these 59 commonly essential genes, 14 genes were exclusively associated with better overall patient survival and 19 with worse overall survival. Notably, a specific molecular signature among the latter, characterized by DDR genes like UBE2T, RFC4, POLQ, BRIP1, and H2AFX showing the weakest dependency scores, but significant upregulation was strongly associated with worse survival. The present study supports the existence and importance of non-oncogenic addiction to DNA repair in cancer and may facilitate the identification of prognostic biomarkers and therapeutic opportunities.

    2021Scientific Reports(2021)引用:12
    引用
    AI阅读
    加入学术空间
    2Shared Heritability and Functional Enrichment Across Six Solid Cancers
    Xia Jiang,Hilary K. Finucane,Fredrick R. Schumacher,Stephanie L. Schmit,Jonathan P. Tyrer,Younghun Han,Kyriaki Michailidou,Corina Lesseur,Karoline B. Kuchenbaecker,Joe Dennis,David V. Conti,Graham Casey,

    An amendment to this paper has been published and can be accessed via a link at the top of the paper.

    2019Nature Communications(2019)引用:156
    引用
    AI阅读
    加入学术空间
    3Prostate-specific Antigen Velocity in a Prospective Prostate Cancer Screening Study of Men with Genetic Predisposition
    Christos Mikropoulos,Christina G Hutten Selkirk,Sibel Saya,Elizabeth Bancroft,Emily Vertosick,Tokhir Dadaev,Charles Brendler,Elizabeth Page,Alexander Dias,D Gareth Evans,Jeanette Rothwell,Lovise Maehle,

    This corrects the article DOI: 10.1038/bjc.2017.429.

    2018British journal of cancer(2018)引用:19
    引用
    AI阅读
    加入学术空间
    4Antitumor Activity of Trabectedin and Lurbinectedin in Germline BRCA2 Carriers with Metastatic Breast Cancer (MBC) As Compared to BRCA1 Carriers: Analysis of Two Phase II Trials.
    Judith Balmana Gelpi,Jan Antoni Lubinski,Banu Arun,Tomasz Byrski,Melinda L. Telli,Steven J. Isakoff,Cristian Fernandez,Pilar Lardelli,Carmen Maria Kahatt,Arturo Soto-Matos,Suzette Delaloge

    574 Background: BRCA 1/2-associated breast cancer share homologous recombination deficiency, but also have independent and potentially actionable roles. Novel drugs with innovative mechanism of action, lacking cross-resistance with other used agents are needed for BRCA 1/2 MBC. Trabectedin (TR) and its analog, lurbinectedin (L), have shown to be active in BRCA 1/2 MBC. This study was sought to determine if there was a difference in activity of these agents between BRCA1 and 2 carriers. Methods: Safety and efficacy in MBC BRCA 1/2 were analyzed in 2 separate phase II trials of single agent TR and L. Results: 88 patients were evaluated: 34 with TR, 54 with L. Median age: 46 and 43, respectively. Median (range) prior chemotherapy lines: TR, 4 (1-10); L, 2 (0-5). Clinical responses were seen in the 2 trials (see table) and were higher in BRCA2 than in BRCA1 (33% vs 9% with TR and 61% vs 26% with L). Main adverse event was myelosuppression (grade 3-4 neutropenia / thrombocytopenia / febrile neutropenia: TR, 62.1%/24.3%/10.8% L, 66.7%/20.4%/20.4%). Non-hematological toxicity was mostly grade 1-2: fatigue, nausea/vomiting and high transaminases (grade 3/4 TR, 40.5%, L 18.5%). Conclusions: Remarkable activity of trabectedin and lurbinectedin as single agents was observed in BRCA 2 associated MBC. This finding warrants further investigation. One potential mechanistic rationale is the role of both lurbinectedin and BRCA 2 in transcription. Safety was acceptable and manageable in both studies. Clinical trial information: NCT01525589. [Table: see text]

    2017Journal of Clinical Oncology(2017)
    引用
    AI阅读
    加入学术空间
    5Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study.
    S Delaloge,R Wolp-Diniz,T Byrski,J L Blum,A Gonçalves,M Campone,P Lardelli,C Kahatt,A Nieto,M Cullell-Young,J Lubinski

    Breast cancer is a heterogeneous disease defined by both germline and somatic abnormalities. In preclinical models, tumors carrying homologous recombination defects are highly sensitive to trabectedin. This phase II trial evaluated the efficacy and safety of trabectedin in BRCA1/2 germline mutation carriers with pretreated metastatic breast cancer (MBC).Trabectedin 1.3 mg/m(2) as a 3-h i.v. infusion was administered every 3 weeks until progression or intolerance. The primary efficacy end point was the objective response rate (ORR) as per RECIST. Secondary efficacy end points comprised time-to-event end points, and changes in tumor volume and expression of tumor marker CA15.3. Safety was evaluated using the NCI-CTCAE.Forty BRCA1/2 germline mutation carriers with MBC were included. Confirmed partial response (PR) occurred in 6 of 35 assessable patients [ORR = 17%; 95% confidence interval (CI) 7% to 34%] and lasted 1.4-6.8 months. Median PFS was 3.9 months (95% CI 1.6-5.5 months). Eight patients (21%) showed changes in tumor volume, and 14 (40%) a clinical benefit. Trabectedin-related adverse events were generally mild/moderate, the most common being fatigue, nausea, constipation and anorexia. Severe laboratory abnormalities (neutropenia, transaminase increases) were mostly transient and noncumulative, and were managed by dose adjustments.With the caveat of the limited patient number, trabectedin monotherapy showed activity and was well tolerated in heavily pretreated MBC patients selected for germline BRCA mutation. These results prompt further evaluation of trabectedin alone or combined with other specific drugs in this indication.NCT00580112.

    2014Annals of Oncology(2014)引用:47
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 33 篇论文

    合作机构(100)

    纽卡斯尔大学 (澳大利亚)合作论文 5
    约翰·亨特医院合作论文 4
    McGill University合作论文 4
    Pomeranian Medical University合作论文 4
    卡罗林斯卡大学医院合作论文 4
    Coalition for Research in Women's Health合作论文 3
    Latvian Biomedical Research and Study Centre合作论文 3
    不列颠哥伦比亚癌症机构合作论文 3
    纪念斯隆凯特琳癌症中心合作论文 3
    挪威奥斯陆大学医院合作论文 3

    机构统计